David W. Schulz
Pfizer (United States)(US)
Publications by Year
Research Areas
Neurotransmitter Receptor Influence on Behavior, Receptor Mechanisms and Signaling, Neuroscience and Neuropharmacology Research, Nicotinic Acetylcholine Receptors Study, Synthesis and Biological Evaluation
Most-Cited Works
- → Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation(2005)930 cited
- → Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid(2006)533 cited
- → CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.(1996)378 cited
- → Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.(1995)320 cited
- → Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions(1981)203 cited
- → 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1*) agonist and rotationally restricted phenolic analog of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole(1990)160 cited
- → SCH-23390: A selective D1 dopamine antagonist with potent D2 behavioral actions(1984)158 cited
- → Glucose 1,6-Diphosphate Formation by Phosphoglucomutase in Mammalian Tissues(1969)133 cited
- → Cochicine-induced granule cell loss in rat hippocampus: Selective behavioral and histological alterations(1986)119 cited
- → Binding of [3H]SCH23390 in Rat Brain: Regional Distribution and Effects of Assay Conditions and GTP Suggest Interactions at a D1‐Like Dopamine Receptor(1985)117 cited